Депрессии у больных хроническим вирусным гепатитом С, получающи противовирусную терапию
Диссертация
Анализируя литературные источники, можно отметить отсутствие согласия исследователей по поводу многих фактов: наличие или отсутствие психопатологической симптоматики на фоне применения интерферонао патогенетической и этиологической роли интерферонов в развитии психопатологической симптоматикио значимости факторов риска для развития индуцированной интерфероном депрессии. Нет согласия о сроках… Читать ещё >
Список литературы
- Аведисова А.С. Современная классификация антидепрессантов: возможности повышения эффективности и безопасности. Психиатрия и психофармакотерапия. 2000., Т. 2, № 1, с. 6−11.
- Бабкин Д.И. Психические нарушения у больных хроническими диффузными заболеваниями печени. Дисс.канд. мед. наук, М., 2001.
- Благовидова О.Б. Аффективные расстройства при гипертонической болезни. Автореферат дисс.канд. мед. наук., М., 2001.
- Бобров А.С. Эндогенная депрессия. Иркутск, РИО ГИУВа, 2001., 384 с.
- Вейн A.M., Вознесенская Т. Г., Голубев В.JL, ДюковаГ.М. Депрессии в неврологической практике (клиника, диагностика, лечение). М., 1998., 328с.
- Вельтищев Д.Ю. Многоликий эглонил 2001., Российский медицинский журнал, Том 9 № 25, с.13−16
- ВойцехВ.Ф. О критериях прогноза депрессий. Журн. Неврол. и психиатрии им. С. С. Корсакова, 1990, № 4, с. 71 75.
- Данные Федерального центра Госсанэпиднадзора МЗ РФ, 2000
- Дробижев М.Ю. Антидепрессанты в психосоматике. Психиатрия и психофармакотерапия. 2001, № 3, стр. 15−19.
- Иванов С.В. Переносимость современных антидепрессантов как один из приоритетных факторов при терапии депрессивных состояний. Психиатрия и психофармакотерапия. 2004, № 2, стр. 1114.
- Ивашкин В.Т. Терминология хронических гепатитов, реакции отторжения печеночного аллотрансплантата и узловых поражений печени. Русский медицинский журнал. 1995. № 6. С. 26 30.
- Игнатова Т.М., Апросина З. Г., Серов В. В., Мухин Н. А., Крель П. Е., Семенкова Е. Н., Попова И. В., ТанащукЕ.Л. Внепеченочные проявления хронического гепатита. Журн. Терапевтический Архив, 1998, № 70(11) С. 9−16
- ИоанидиЕ.А. Клинико-иммунологическая характеристика и наш опыт лечения гемоконтактных вирусных гепатитов. Новые лекарства и новости фармакотерапии. 2000. № 8. С. 3 6.
- Ишутина Н. П, Раева Т. В. Депрессивные расстройства и их терапия в дерматологической практике. Томск, 1999.
- Краснов В.Н. Клинико-патогенетические закономерности динамики циркулярных депрессий. Автореф. дисс.докт. Мед. наук. М., 1987.
- Краснов В.Н. Депрессия как диагностическая и терапевтическая проблема в общемедицинской практике. М., Медикал Маркет, 1999., с. 22−25.
- Лопаткина Т.Н. Клиника гепатита С. Вирусные гепатиты: достижения и перспективы. 1997. № 1, с. 12−16.
- Львов Д.К., Самохвалов Е. И., Миширо С., ТсудаФ., Селиванов Н. А., Окамото X и др. Закономерности распространения вируса гепатита С и его генотипов в России и странах СНГ. Вопросы вирусологии, 1997, № 4, стр. 157−161.
- Малин Д.И. Лекарственные взаимодействия психотропных средств (часть I и II). Психиатрия и психофармакотерапия. 2000, том 2, № 6, стр. 17−24- 2001 том 3, № 1, с. 15−21.
- Маляров С. А, Шевчук И. Д. Медикаментозное лечение психических расстройств. Психофармакотерапевтический справочник, М., 1997., 383 с.
- Минушкин О.Н., Масловский Л. В. Этиотропная терапия хронических вирусных гепатитов. Кремлевская медицина- Клинический вестник. № 1, 2000 г. С. 16−18.
- Мосолов С.Н. Клиническое применение современных антидепрессантов. С.-Петербург, 1995. с. 502−513.
- Мосолов С.Н., Бовин Р. Я., Пантелеева Г. П. Клиническая эффективность и переносимость препарата коаксил (тианептин) при терапии депрессии. Журн. Неврол. и психиатрии им. С. С. Корсакова, 2003, № 8, с. 29—34.
- Мухин Н. А, Апросина З. Г, Серов В. В. Хронические вирусные гепатиты — от этиологии к лечению. М., 2004, ООО Издательский дом «Русский врач».
- Надинская М.Ю. Лечение хронических вирусных гепатитов. Российский медицинский журнал 2002, Т 12, № 29. С. 9−12
- НедогодаВ.В. Фармакотерапия хронических диффузных заболеваний печени. Новые лекарства и новости фармакотерапии. 2000. № 6. С. 3−16.
- Паламарчук С.А. Ремерон (миртазапин) антидепрессант нового поколения. Таврический журнал психиатрии., — 2000. Т.4., № 1, с. 1214.
- Ресина И. А. Выявление состояний депрессии и тревоги, качество жизни у больных с хронической сердечной недостаточностью
- Актуальные вопросы военной и практической медицины. Сб. трудов II научно-практической конференции врачей Приволжско-Уральского военного округа. Оренбург 2001, С. 51−53.
- Смулевич А.Б. Депрессия в общемедицинской практике. — Москва, 2002- 158 с.
- Смулевич А.Б., Дробижев М. Ю. Психические нарушения при инфаркте миокарда. В кн. Сыркин A.JI. Инфаркт миокарда. М., Медицинское информационное агентство. 1998, с. 129−138.
- ТигановА.С. Аффективные расстройства и синдромообразование. Журн. Неврол. и психиатрии им. С. С. Корсакова, 1999, т. 99, № 1, с. 8—10.
- Тиганов А.С. под ред. Руководство по психиатрии. М., «Медицина», 1999- с. 40−44.
- Трофимова О.В., Точилов В. А., Болдуева С. М. Лечение паксилом (пароксетином) тревожных депрессий у больных в раннем постинфарктном периоде. Журн. Лечащий Врач, 2003, № 07, С. 56−58
- Цивилько М.А. Психические нарушения у больных хронической почечной недостаточностью. Журн. Неврол. и психиатрии им. С. С. Корсакова, 1971, т. 71, № 12, с. 1835—1841.
- Abraham HD, Degli-Esposti S, Marino L: Seroprevalence of hepatitis С in a sample of middle class substance abusers. J Addict Disease 1999- 18:77−86
- Ademmer K, Beutel M, Bretzel R et al. Suicidal ideation with IFN-alpha and ribavirin in a patient with hepatitis C. Psychosomatics 42(4):365−367.
- Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, et al. The prevalence of hepatitis С virus infection in the United States, 1988 through 1994. N Engl J Med 1999−341:556−562
- Anisman H, Kokkinidis L, Merali Z. Further evidence for the depressive effects of cytokines: Anhedonia and neurochemical changes Brain Behav Immun 2002 Oct-16(5):544
- Anisman H, Merali Z. Cytokines, stress and depressive illness: brain-immune interactions. // Ann Med. 2003−35(1):2−11.
- Anisman H, Ravindran AV, Grith J, Merali Z. Interleukin-lb production in dysthymia before and after pharmacotherapy. Biological Psychiatry 1999, 46, 1649−1655.
- Anttila S, Leinonen E. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev 2001- 7:249−264.
- Asnis GM, De La Garza R 2nd, Kohn SR, Reinus JF, Henderson M, Shah J. IFN-Induced Depression: A Role for NSAIDs. Psychopharmacol Bull. 2003 Summer- 37(3):29−50.
- Aubert A, Vega C, Dantzer R, Goodall G. Pyrogens specifically disrupt the acquisition of a task involving cognitive processing in the rat. Brain Behav Immun. 1995−9:129−148.
- Banks, W.A. Cytokines, CVSs, and the blood-brain barrier. In R. Ader, D. Felten, & N. Cohen (Eds.), Psychoneuroimmunology, 2001, (pp. 483 498). New York: Academic Press.
- Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An Inventory for Measuring Dpression. Arch Gen Psychiatry, Vol. 4, June 1961.
- Berk M, Wadee AA, Kuschke RH, et al: Acute phase proteins in major depression. J Psychosom Res 43:529−534, 1997
- Benkert O. et al. Mirtazapine compared with paroxetine in major, depression. J Clin Psychiatry, 2000- 61: 656−663
- Bonaccorso S., Meltzer H. and Maes M. Psychological and behavioural effects of interferons Current Opinion in Psychiatry 2000, 13:673−677
- Booth JCL, O’Grady J, Neuberger J. Clinical guidelines on themanagement of hepatitis C. Gut 2001- 49(suppl 1):1−21.
- Brown RR, Ozaki Y, Datta SP, Borden EC, Sondel PM, Malone DG. Implications of interferon-induced tryptophan catabolism in cancer, autoimmune diseases and AIDS. Adv Exp Med Biol 1991−294:425−435
- Capuron L, Gumnick JF, Musselman DL, et al. Neurobehavioral effects of interferon-a in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002- 26:643−652.
- Capuron L, Lamarque D, Dantzer R, Goodall G. Attentional and mnemonic deficits associated with infectious disease in humans. Psychological Medicine 1999- 29, 291−297.
- Castera L, Zigante F, Bastie A, Buffet C, Dhumeaux D, Hardy P. Incidence of interferon alfa-induced depression in patients with chronic hepatitis C. Hepatology 2002−35:978−979.
- Clark CH, Mahony JS, Clark DJ, et al. Screening for depression in a hepatitis С population: the reliability and validity of the Center for Epidemiologic Studies Depression Scale (CES-D). J Adv Nurs 2002- 40:361−369.
- Connor, T.J., Leonard, B.E. Depression, stress and immunological activation: The role of cytokines in depressive disorders. Life Sciences, 2000. 62, 583−606.
- Cornelius J, Salloum I, Ehler J, et al. Fluoxetine in depressed alcoholics. A double-blind, placebo-controlled trial. Arch Gen Psychiatry 1997- 54:700−705.
- Crone C- Gabriel MG. Comprehensive rewiev of hepatitis С for psychiatrists: risk, screening, diagnosis, treatment and interferon-based therapy complications. J Psych Pract, 2003- 9:93−110.
- Crone C- Gabriel GM, Wise TN. Managing the neuropsychiatric side effects of interferon-based therapy for hepatitis C. Cleveland Clinic Journal Of Medicine Volume 71 • Supplement 3 May 2004 P.27−32
- Dantzer, R. Cytokine-induced sickness behavior: where do we stand? Brain, Behavior, and Immunity, 2001,15, 7−24.
- Davis GL, Balart LA, Schiff ER, et al: Treatment of chronic hepatitis С with recombinant interferon alfa: a multicenter randomized, controlled trial. N Engl J Med 1989- 321:1501−1510
- De La Garza II R, Fabrizio KR, Radoi G-E, Vlad T, Asnis GM. The nonsteroidal anti-inflammatory drug diclofenac sodium attenuates lipopolysaccharide-induced corticosterone release and depressive-like behavior. FASEB J. 2003−17:A1024.
- De Lima M.S.,. Hotoph M and Wessely S., The efficacy of drug treatments for dysthymia: a systematic review, and meta-analysis. Psychol Med 29 (1999), pp. 1273−1289.
- Delbressine LP, Vos RM: The clinical relevance of preclinical data: Mirtazapine, a model compound. J Clin Psychopharmacol 17: 29S-33S, 1997 (suppl 1)
- Delbressine LPC, Moonen MEG, Kaspersen FM, et al: Pharmacokinetics and biotransformation of mirtazapine in human volunteers. Clin Drug 1998, Invest 15:45−55
- DeVane CL. Pharmacokinetics of the newer antidepressants: clinical relevance. Am J Med. 1994−97(suppl 6A):13S-23S
- Dieperink E, Ho SB, Thuras P, Willenbring ML. A prospective study of neuropsychiatric symptoms associated with interferon-a-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics 2003- 44:104−112.
- Dieperink E, Willenbring M, Ho SB: Neuropsychiatric symptoms associated with hepatitis С and interferon alpha: a review. Am J Psychiatry 2000- 157:867−876
- Dominique, L. Musselman, M.D., David H. et al Paroxetine for the prevention of depression induced by high-dose interferon alfa n Engl J, 2001. Med, Vol. 344, No. 13 March 29,
- Dwight MM, Kowdley KV, Russo JE, et al: Depression, fatigue, and functional disability in patients with chronic hepatitis C. J Psychosom Res 2000- 49:311−317
- EASL International Consensus Conference on Hepatitis C. Paris, 26−28 February 1999, Consensus Statement. European Association for the Study of the Liver. J Hepatol 1999- 30:956−961.
- Edwards G, Anderson I. Systematic review and guide to selective serotonin reuptake inhibitors. Drugs 1999−57:507−533
- Ek, M., Engblom, D., Saha, S., Blomqvist, A., Jakobsson, P., & Ericsson-Dahlstrand, A. (2001). Pathway across the blood-brain barrier. Nature, 410, 430−431.
- Fava M, Kendler KS. Major depressive disorder. Neuron. 2000−28:335−341.
- Farah A Interferon-induced depression treated with citalopram. J Clin Psychiatiy (2002), 63(2): 166−167.
- Finley PR. Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions. Ann Pharmacother. 1994−28:1359−1369.
- Fontana RJ, Hussain KB, Schwartz SM, Moyer CA, Su GL, Lok AS. Emotional distress in chronic hepatitis С patients not receiving antiviral therapy J Hepatol. 2002 Mar-36(3):401−7.
- Fontana RJ. Neuropsychiatric toxicity of antiviral treatment in chronic hepatitis C. Dig Dis 2000- 18:107−116.
- Frasure-Smith N, Lesperance F, Talajic M. Depression following myocardial infarction: impact on 6-month survival. JAMA 1993, 270:1819−25.
- Fried MW, Shiffman ML, Reddy R, Smith C, Marinos G, Gon9ales FL Jr, Haussinger D, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis С virus infection. N Engl J Med 2002−347:975−982
- Fukunishi К., Tanaka H., Maruyama J. et al., Burns in a suicide attempt related to psychiatric side effects of interferon. Bums 24 (1998), pp. 581 583
- Gibertini M. IL1 beta impairs relational but not procedural rodent learning in a water maze task. Adv Exp Med Biol. 1996- 402:207−217.
- Gleason ОС, Yates WR, Isbell MD, Philipsen MA. An open-label trial of citalopram for major depression in patients with hepatitis C. // J Clin Psychiatry. 2002 Mar- 63(3): 194−8.
- Gleason ОС, Yates WR, Philipsen MA, Isbell MD, Pollock BG. Plasma levels of citalopram in depressed patients with hepatitis C. Psychosomatics. 2004 Jan-Feb- 45(1): 29−33.
- Gleason ОС, Yates WR. Five cases of interferon-alfa-induced depression treated with antidepressant therapy. Psychosomatics 1999−40:510−2.
- Gochee J. W. Association Between Apolipoprotein E epsilon.4 and Neuropsychiatric Symptoms During Interferon [alpha] Treatment for Chronic Hepatitis C. American Psychiatric Press, Inc. Jan/Feb 2004
- Gohier B, Goeb JL, Rannou-Dubas K, Fouchard I, Cales P, Garre JB. Hepatitis C, alpha interferon, anxiety and depression disorders: a prospective study of 71 patients. World J Biol Psychiatry. 2003−4(3):115−8.
- Goldsmith RJ, Mindrum G, Myaing M. Psychiatric assessment of patients with hepatitis С virus before initiating interferon treatment. Psychiatric Annals 2003- 33(6):369−376.
- Gregory E. Miller, Ph.D. How Does Stress Get Inside the Body to Influence Depression? Some Answers from the Perspective of Behavioral Immunology Affective Neuroscience of Psychopathology, New York, NY: Oxford University Press. 30 p.
- Gregory M. Asnis, MD, Richard De La Garza et al. IFN-Induced Depression: A Role for NSAIDs • Psychopharmacology Bulletin: Summer 2003 — Vol. 37 ¦ No. 3 • 29
- Hardy, P. Trouble depressifs et interferon alpha. Gastroenterol. Clin. Biol. 20 1996, 255−257
- Hauser P, Khosla J, Aurora H, et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry. 2002−7(9):942−7.
- Hauser P, Soler R, Reed S, et al: Prophylactic treatment of depression induced by interferon-alpha. Psychosomatics 41:439−441, 2000
- Heeringa M Honkoop P de Man RA Feenstra J Smits CM SmitsCM Major psychiatric side effects of interferon alpha-2b Ned Tijdschr Geneeskd 1998 Jul 142:1618−21
- Hoffman RG, Cohen MA, Alfonso CA et al. Treatment of interferon-induced psychosis in patients with comorbid hepatitis С and HIV. Psychosomatics 2003- 44(5):417−420.
- Holsboer F The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000 23, 477−501.
- Holsboer F. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J Psychiatr Res. 1999−33:181−214.
- Horikawa N, Yamazaki T, Izumi N, Uchihara M. Incidence and clinical course of major depression in patients with chronic hepatitis type С undergoing interferon-alpha therapy: a prospective study. // Gen Hosp Psychiatry. 2003 Jan-Feb-25(l):34−8.
- Horsburgh K, McCarron MO, White F, Nicoll JA: The role of apolipoprotein E in Alzheimer’s disease, acute brain injury and cerebrovascular disease: evidence of common mechanisms and utility of animal models. Neurobiol Aging 2000- 21:245−255
- Hosoda S, Kohno M, Kumada H. Psychiatric symptoms related to interferon treatment for chronic hepatitis Seishin Shinkeigaku Zasshi. 2003- 105(6):768−86.
- Hunt CM, Dominitz JA, Bute BP, et al: Effect of interferon-treatment on chronic hepatitis С on health-related quality of life. Dig Dis Sci 1997- 42:2482−2486
- Iwarson S. The natural course of chronic hepatitis C. FEMS Microbiology Rewieves 1994- 14:201−4.
- Janssen HL, Brouwer JT, van der Mast RC, Schalm SW. Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J Hepatol. 1994−21:241−243.
- Johnson ME, Fisher DG, Fenaughty A, Theno SA: Hepatitis С virus and depression in drug users. Am J Gastroenterol 1998- 93:785−789
- Jones TH, Wadler S, Hupart KH: Endocrine-mediated mechanisms of fatigue during treatment with interferon-alpha. Semin Oncol 25:54−63, 1998
- Kanno A, Yamada M, Abe M, Okamoto Y. A case of interferon alpha-induced manic psychosis in chronic hepatitis. Tohoku J Exp Med 1999- 187:79−82.
- Kennedy SH, Dickens SE, Eisfeid BS, Bagby RM. Sexual dysfunction before antidepressant therapy in major depression. J Affect Dis. 1999- 56:201−208.
- Kirkwood K.M., Bender C., Agarwala S. et al, Mechanisms and Management of Toxicities Associated With High-Dose Interferon Alfa-2b Therapy J Clin Oncol 2002 P.20:3703−3718.
- Konan KW, Taylor MW (1996). Importance of the two interferon-stimulated response element (ISRE) sequences in the regulation of the human indoleamine 2,3-dioxygenase gene. Journal of Biological Chemistry 271,19 140−19 145.
- Kontorinis N., Agarwa K. l, Current Status of the Use of Growth Factors and Other Adjuvant Medications in Patients Receiving Peginterferon and Ribavirin Vol. 4 Suppl. 1 2004 Keviews in gastroenterological disorders 39−47
- Koskinas J, Merkouraki P, Manesis E, Hadziyannis S. Assessment of depression in patients with chronic hepatitis: effect of interferon treatment. Dig Dis. 2002−20(3−4):284−8.
- Kraus M.R., Schafer A. Paroxetine for the Prevention of Depression Induced by Interferon Alfa The New England Journal of Medicine Volume 345:375−376 August 2, 2001. Number 5
- Kraus MR, Schafer A, Csef H, et al: Emotional state, copingstyles, and somatic variables in patients with chronic hepatitis C. Psychosomatics 2000−41:377−384
- Kraus MR, Schafer A, Faller H, Csef H, Scheurlen M. Psychiatric symptoms in patients with chronic hepatitis С receiving interferon alfa-2b therapy. J Clin Psychiatry. 2003 Jun-64(6):708−14.
- Kubera M, Kenis G, Bosmans E, Zieba A, Dudek D, Nowak G, MaesM (2000c). Plasma levels of interleukin-6, interleukin-10, and interleukin-1 receptor antagonist in depression: comparison between the acute state and after remission.
- Kumpfel T, Then Bergh F, Pollmaicher T, Holsboer F, Trenkwalder C. Acute effects of interferon beta-laon plasma cytokine levels in patients with MS. Neurology. 2000−55:1231−1233.
- Kunkel EJ, Kim JS, Hann HW, Oyesanmi O, Menefee LA, Field HL, Lartey PL, et al. Depression in Korean immigrants with hepatitis В and related liver diseases. Psychosomatics 2000−41:472−480.
- Kutner КС, Erlanger DM, Tsai J, Jordan B, Relkin NR: Lower cognitive performance of older football players possessing apolipoprotein E epsilon4. Neurosurgery 2000- 47:651−657
- Landmann R, Schaub B, Link S, Wacker HR (1997). Unaltered monocyte function in patients with major depression before and after three months of antidepressive therapy. Biological Psychiatry 41, 675−681.
- Lang JP, Meyer N, Doffoel M. Praticien Hospitalier Benefits of a preventive psychiatric accompaniment in patients Hepatitis С Virus seropositive (HCV): prospective study concerning 39 patients Encephale. 2003 Jul-Aug-29(4 Pt l):362−5
- Lang JP, Michel L, Halleguen О Treatment of affective disorder in hepatitis C. A prospective study in 50 patients // Ann Med Interne (Paris). 2002 Nov- 153(7 Suppl):2S22−30.
- Leu SJ, Shiah IS, Yatham LN, Cheu YM, Lam RW (2001). Immune-inflammatory markers in patients with seasonal affective disorder: effects of light therapy. Journal of Affective Disorders 63, 27−34.
- Lepine JP, Altamura C, Ansseau et al. Tianeptine and paroxetine in major depressive disorder, with a special focus on the anxious component in depression: an international, 6-week, double-blind study. Human Psychopharmacol. 2001- 16:219−227.
- Lichtman SW, Seliger G, Tycko B, Marder K: Apolipoprotein E and functional recovery from brain injury following postacute rehabilitation. Neurology 2000- 55:1536−1539
- Licinio J, Wong ML, Gold PW: Localization of interleukin-1 receptor antagonist mRNA in rat brain. Endocrinology 129:562−564, 1991
- Loftis JM, Hauser P. Comanagement of depression and HCV treatment. Psychiatr Ann 2003- 33:385−391.
- Loo H- Saiz-Ruiz J- Costa e Silva JACE- Ansseau M- Herrington R- Vaz-Serra A- Dilling H- de Risio S. Efficacy and safety of tianeptine in the treatment of depressive disorders in comparison with fluoxetine. J Affect Disord — 1999 Dec- 56(2−3): 109−18.
- Mace S, Taylor D. Selective serotonin reuptake inhibitors: a review of efficacy and tolerability in depression. Expert Opin Pharmacother 2000−1:917−933.
- Maes M, Bonaccorso S. Lower activities of serum peptidases predict higher depressive and anxiety levels following interferon-alpha-based immunotherapy in patients with hepatitis C. Acta Psychiatr Scand. 2004 Feb- 109(2): 126−31.
- Maes M, Song C, Lin AH, et al. Negative immunoregulatory effects of antidepressants: inhibition of interferon-gamma and stimulation of interleukin-10 secretion. Neuropsychopharmacology 1999- 20: 370−379.
- Maes M, Vandoolaeghe E, Van Hunsel F, Bril T, Demedts P, Wauters A, Neels H Immune disturbances in treatment-resistant depression: modulation by antidepressive treatment. Human Psychopharmacology 1997 12, 153−162.
- Maes M. Evidence for an immune response in major depression: A review and hypothesis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1995, 19, 11−38.
- Maier S.F., Goehler L.E., Fleshner M., Watkins L.R. The role of the vagus nerve in cytokineto brain communication. Annals of the New York Academy of Sciences, 1998. 840, 289−300.
- Maier S.F., Watkins L.R. Cytokines for psychologists: Implications of bidirectional immune-tobrain communication for understanding behavior, mood, and cognition. Psychological Review, 1998 105, 83−107.
- Maj M. Depressive syndromes and symptoms in subjects with human immunodeficiency virus (HIV) infection. British Journal of Psychiatry 1996, 168, 117−122.
- Makino M, Kitano Y, Hirohashi M, Takasuna K. Enhancement of immobility in mouse forced swimming test by treatment with human interferon. Eur J Pharmacol 1998−356:1−7
- Malaguarnera M., Di Fazio I., Restuccia S., Pistone G., Ferlito L. et al. Interferon alpha-induced depression in chronic hepatitis С patients: comparison between different types of interferon alpha. Neuropsychobiology 1998 37:93−7
- Malek-Ahmadi P. Mood disorders associated with interferon treatment: theoretical, and practical considerations. Ann Pharmacother 35 2001,. 489−495
- Malek-Ahmadi P, Ghandour E. Bupropion for Treatment of Interferon-Induced Depression (July/August). Ann Pharmacother. 2004, Jul-Aug- 38(7−8):1202−5.
- Malka R, Loo H, Ganry H, Souche A, Marey C, Kamoun A. Long-term administration of tianeptine in depressed patients after alcohol withdrawal. Br J Psych. 1992- 160:66−71.
- McAllister-Williams R. H.,. Young A. H Antidepressant response reversed by interferon The British Journal of Psychiatry (2000) 176: 93 2000
- McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK: Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998−339:1485−1492.
- Meyers CA, Valentine AD. Neurologic and psychiatric adverse effects of immunological therapy. CNS Drugs. 1995−3:56−68.
- Meyers CA: Mood and cognitive disorders in cancer patients receiving cytokine therapy. Adv Exp Med Biol 461:75−81, 1999
- Michael W. Side effects of therapy of hepatitis С and their management. Hepatology. 2002 Nov-36(5 Suppl l):S237−44.
- Miller, A.H., Pariante, C.M., Pearce, B.D. Effects of cytokines on glucocorticoid receptorexpression and function. Advances in Experimental Medicine and Biology, 1999, 461, 107−116.
- Miyaoka H, Otsubo T, Kamijima K, et al: Depression from interferon therapy in patients with hepatitis С (letter). Am J Psychiatry 1999- 156:1120
- Mohr DC, Goodkin DE, Islar J, Hauser SL, Genain CP). Treatment of depression is associated with suppression of nonspecific and antigen-specific T (H)1 responses in multiple sclerosis. Archives of Neurology 2001,58, 1081−1086.
- Montgomery SA: Safety of mirtazapine: A review. Int Clin Psychopharmacol 10:37−45, 1995 (suppl 4)
- Montgomery SA, Asberg MA. New depression scale designed to be sensitive to change. Br J Psychiatry, 1979- 134:382−389.
- Morag M, Yirmiya R, Lerer B, Morag A. Influence of socioeconomic status on behavioral, emotional and cognitive effects of rubella vaccination: a prospective, double blind study. Psychoneuroendocrinology. 1998−23:337−351.
- Morikawa О, Sakai N, Obara H, Saito N. Effects of interferon-alpha, interferon-gamma and cAMP on the transcriptional regulation of the serotonin transporter. Eur J Pharmacol 1998−349:317−324.
- Mulla A, Buckingham JC: Regulation of the hypothalamopituitary-adrenal axis by cytokines. Baillieres Best Pract Res Clin Endocrinol Metab 13:503−521, 1999
- Muller N, Ackenheil M: Psychoneuroimmunology and the cytokine action in the CNS: Implications for psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 22:1−33, 1998
- Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of depression induced by high-dose IFN alfa. N Engl J Med. 2001−344:961−966.
- Natelson BH, Denny T, Zhou XD, LaManca JJ, Ottenweller LE, Tiersky L. DeLuca J, Gause WC Is depression associated with immune activation? Journal of Affective Disorders 1999, 53, 179−184.
- National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology 1997−26(3 suppl 1):2S-10S.
- Neveu P, Castanon N. Is there evidence for an effect of antidepressant drugs on immune function? In: Dantzer R, Wollman EE, Yirmiya R, eds. Cytokines, Stress and Depression. New York: Kluwer Academic/Plenum Publishers- 1999: 267−281.
- O’Connor N. T, Interferon beta, and suicide in multiple sclerosis. Lancet 347 1996, 1417−1418
- Otsubo T, Miyaoka H, Kamijima K, et al: Depression during interferon therapy in chronic hepatitis С patients-a prospective study (Japanese). Seishin Shinkeigaku Zasshi 1997- 99:101- 127
- Pariante CM, Miller AH, Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment., Biol Psychiatry 49: 5, 391 404, Mar 1,2001.
- Pariante CM, Orru MG, Baita A, Farci MG, Carpiniello B: Treatment with interferon-alpha in patients with chronic hepatitis and mood or anxiety disorders. Lancet 1999- 354:131−132
- Pavol MA, Meyers С A, Rexer JL, et al: Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia. Neurology 45:947−950, 1995
- Pessione F, Ramond M, Njapoum C, et al. Cigarette smoking and hepatic lesions in patients with chronic hepatitis C. Hepatology 2001- 34:121— 125.
- Plotsky PM, Owens MJ, Nemeroff CB (1998). Psychoneuroendocrinology of depression. Hypothalamic- pituitary-adrenal axis. Psychiatric Clinics of North America 21, 293−307.
- Pollak Y. Raz Yirmiya R. Cytokine-induced changes in mood and behaviour: implications for 'depression due to a general medical condition', immunotherapy and antidepressive treatment International Journal ofNeuropsychopharmacology 2002, 5, 389−399.
- Pugh RC, Kumagawa K, Fleshner M, Watkins LR, Maier SF. Selective effects of peripheral lipopolysaccharide administration on contextual and auditory-cue fear conditioning. Brain Behav Immun. 1998−12:212−229.
- Raison CL, Borisov AS, Broadwell SD, Capuron L, Woolwine BJ, Jacobson IM, Nemeroff CB, Miller AH. Depression during pegylatedinterferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry. 2005 Jan-66(l):41−8.
- Renault PF Hoofnagle JH Park Y Mullen KD et al. Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med 1997 Sep 147:1577−80
- Rifflet H, Vuillemin E, Oberti F, et al. Interferon et suicide au cours des hepatites virgules chroniques. Gastroenterol Clin Biol 1996- 20:606−607.
- Rifflet H. Vuillemin E. Oberti F Suicidal impulses in patients with chronic viral hepatitis С during or after therapy with interferon alpha Gastroenterol Clin Biol 1998 Mar 22:353−7
- Rothermundt M, Arolt V, Fenker J, Gutbrodt H, Peters M, Kersting A, Kirchner H (2001b). Inflammatory markers in major depression and melancholia. Journal of A. ective Disorders 63, 93−102.
- Ruter E, Degner D, Munzel U. Antidepressant action of sulpiride. Results of a placebo-controlled double-blind trial. Pharmacopsychiatry, 1999, 32,127−135
- Sarbah AS, Younossi ZM. Hepatitis C. An update on the silent epidemic. J Clin Gastroenterol 2000−30:125−143 Medline.
- Schaefer M, Schmidt F, Folwaczny C, Lorenz R, Martin G, Schindlbeck N, Heldwein W, Soyka M, Grunze H, Koenig A, Loeschke K. Adherence and mental side effects during hepatitis С treatment with interferon alfa
- Schaefer M, Schwaiger M, Garkisch AS, Pich M, Hinzpeter A, Uebelhack R, Heinz A, van Boemmel F, Berg T. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol. 2005 Jun-42(6):793−8.
- Schlatter J, Ortuno F, Cervera-Enguix S (2001). Differences in interleukins' patterns between dysthymia and major depression. European Psychiatry 16,317−319.
- Schramm TM, Lawford BR, Macdonald GA, Cooksley WG. Sertraline treatment of interferon- alfa-induced depressive disorder. Med J Aust. 2000−173:359−361.
- Scott LJ, Perry CM. Interferon-alpha-2b plus interferon: a review of its use in the management of chronic hepatitis C. Drugs 2002- 62(5):507−556.
- Seidel A, Arolt V, Hunstiger M, Rink L, Behnisch A, Kirchner H (1996). Major depressive disorder is associated with elevated monocyte counts. Acta Psychiatrica Scandinavica 94, 198−204.
- Shader R.I. Manual of psychiatric therapeutic. 2nd ed. — Little Brown and Сотр. (IUC) Washington, D.C., 1994. — 338 p.
- Sheehan DV, Sheehan K. Int J Psychiat Med., 1983., 12, 243−266. 199. Shimizu H, Ohtani K, Sato N, et al: Increase in serum interleukin-6,plasma ACTH and serum Cortisol levels after systemic interferon-alpha administration. Endocr J 42:551−556, 1995
- Singh N, Gayowski T, Wagener MM, Marino IR. Vulnerability to psychologic distress and depression in patients with end-stage liver disease due to hepatitis С virus. Clin Transplant 1997- 11:406−411
- Sluzewska A, Rybakowski J, Laciak M, Mackiewicz A, Sobieska M, Wiktorowicz К Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine. Annals of the New York Academy of Sciences 1995 762, 474-^76.
- Smith AP, Tyrrell DA, Barrow GI. Mood and experimentally induced respiratory virus infections and illness. Psychol Health. 1992−6:205−212.
- Smith JD: Apolipoprotein E4: an allele associated with many diseases. Ann Med 2000−32:118−127
- Sommer N, Loschmann PA, Northoff GH, et al. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nat Med 1995- 1: 244−248.
- Song C, Leonard BE Anacute phase protein response in the olfactory bulbectomized rat: effect of sertraline treatment. Medical Science Research 1994, 22, 313−314.
- Spangelo BL, Judd AM, Call GB, et al: Role of the cytokines in the hypothalamic-pituitary-adrenal and gonadal axes. Neuroimmunomodulation 2:299−312, 1995
- Stimmel GL, Dopheide JA, Stahl SM: Mirtazapine: An antidepressant with noradrenergic and specific serotonergic effects. Pharmacotherapy 17:10−21, 1997
- Taylor JL, Grossberg SE: The effects of interferon alpha on the production and action of other cytokines. Semin Oncol 25:23−29, 1998 suppl1
- Thompson DS: Mirtazapine for the treatment of depression and nausea in breast and gynecological oncology. Psychosomatics 41:356−359, 2000
- Tomoji Т., Chihiro Т., Osamu N., Ken T. Masaru Y. Prevention and Treatment of Interferon-induced Mental Disorders Jpn Pharmacol Ther 1997 — 24: 1137−1140
- Trask PC, Esper P, Riba M, et al: Psychiatric side effects of interferon therapy: Prevalence, proposed mechanisms, and future directions. J Clin Oncol 18:2316−2326, 2000
- Valentine AD, Meyers С A, Kling MA, et al: Mood and cognitive side effects of interferon-alpha therapy. Semin Oncol 25:39−47, 1998
- Vane JR, Bakhle YS, Bolting RM: Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998- 38:97−120
- Vassilopoulou-Sellin R: Endocrine effects of cytokines. Oncology (Huntingt) 8:43−46, 49- discussion 49−50, 1994
- Wasley A, Alter M. Epidemiology of hepatitis C. Geographical differences and temporal trends. Semin Liver Dis 2000: 20:1−16.
- Weinrieb RM, Auriacombe M, Lynch KG, et al. A critical review of selective serotonin reuptake inhibitor-associated bleeding: balancing the risk of treating hepatitis C-infected patients. J Clin Psychiatry 2003- 64:1502−1510.
- Windemuth D, Bacharach-Buhles M, Hoffmann K, Altmeyer P. Depression and suicidal intentions as a side effect of high dosage interferon alpha therapy: 2 cases. Hautarzt 1999- 50:266−269.
- Wolkowitz OM, Reus VI: Treatment of depression with antiglucocorticoid drugs. Psychosom Med 61:689−711, 1999
- World health organization. Global surveillance and control of hepatitis C. J Viral Hepatitis. 1999- 6:35−47.
- Xia Z, DePierre JW, Nassberger L. Tricyclic antidepressants inhibit IL-6, IL-1 В and TNF- release in human blood monocytes and IL-2 and interferon- in T cells. Immunopharmacology 1996- 34: 27−37.
- Yamano M, Yuki H, Yasuda S, Miyata K. Corticotropin-releasing hormone 1 receptors mediate consensus interferon-alpha YM643-induced depression-like behavior in mice. J Pharmacol Exp Ther 2000−292:181−7.
- Yirmiya R. Behavioral and psychological effects of immune activation: implications for «depression due to a general medical condition.» Curr Opin Psychiatry. 1997−10:470−476.
- Yovtcheva SP, Rifai MA, Moles JK, Van Der Linden BJ. Psychiatric Comorbidity Among Hepatitis C-Positive Patients. Psychosomatics 42:5, September-October 2001.